$TRAX

Wells Fargo Initiates First Tracks Biotherapeutics at Overweight

First Tracks Biotherapeutics (TRAX) has an average rating of buy and mean price target of $38.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Piper Sandler Initiates Coverage on First Tracks Biotherapeutics With Overweight Rating, $54 Price Target

First Tracks Biotherapeutics, Inc. (TRAX) has an average rating of Buy and mean price target of $39.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

HC Wainwright Initiates First Tracks Biotherapeutics at Buy

First Tracks Biotherapeutics (TRAX) has an average rating of buy and mean price target of $37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Leerink Partners Initiates Coverage on First Tracks Biotherapeutics With Outperform Rating

First Tracks Biotherapeutics, Inc. (TRAX) has an average rating of Buy and mean price target of $38.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

JPMorgan Initiates Coverage on First Tracks Biotherapeutics With Overweight Rating

First Tracks Biotherapeutics, Inc. (TRAX) has an average rating of Buy and mean price target of $38.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Barclays Initiates First Tracks Biotherapeutics at Overweight

UBS Initiates Coverage on First Tracks Biotherapeutics With Buy Rating, $45 Price Target

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics; Shares Surge

AnaptysBio (ANAB) said Monday that it has completed the spinoff of its biopharma operations business First Tracks Biotherapeutics.Under the terms of the spinoff, Anaptys shareholders received one share of First Tracks for every share of Anaptys owned as of the close of business on April 6. First Tracks Bio common stock were set to begin trading Monday on the Nasdaq Global Select Market under the ticker symbol "TRAX."The company said it will now exclusively manage its financial collaborations with GSK (GSK) and Vanda for cancer medicine Jemperli and generalized pustular psoriasis treatment imsidolimab, respectively.Shares of AnaptysBio were up close to 8% in recent trading on Monday.Price: $48.39, Change: $+3.39, Percent Change: +7.53%